Objective: To investigate the utility associated with subcutaneous infusion (deferoxamine) compared with once-daily oral administration (deferasirox) of iron chelation therapy. Methods: Interviews using the time trade-off technique were used to estimate preferences (utility) for health states by finding the point at which respondents were indifferent between a longer but lower quality of life (QoL) and a shorter time in full health. Participants (n = 110) were communitybased, 51% women, median age 35 years, from four regions in Sydney, Australia. Respondents rated three health states involving equal outcomes for people with thalassemia but with different treatment modalities for iron chelation; an "anchor state" describing a patient receiving iron chelation without administration mode specified, anchor state plus iron chelation via subcutaneous infusion, and anchor state plus iron chelation through once-daily oral medication. Results: On an interval scale between 0 (death) and 1 (full health), median (interquartile range) utility of 0.80 (0.65-0.95) for the anchor state, 0.66 (0.45-0.87) for subcutaneous infusion, and 0.93 (0.80-0.97) for once-daily oral administration was obtained. The mean (median) difference of 0.23 (0.27) between the two treatments was statistically significant (Wilcoxon-signed rank test, P < 0.001). Subcutaneous infusion was associated with a mean (median) utility 0.13 (0.14) lower than the anchor state (P < 0.001), and once-daily oral treatment had a utility 0.10 (0.13) higher (P < 0.001). Conclusion: Community respondents associate oral administration of an iron chelator such as deferasirox with enhanced QoL compared with subcutaneous treatment. Assuming equal safety and efficacy, QoL gains from oncedaily oral treatment compared with subcutaneous infusion are significant.
Introduction
The health-related quality of life (HRQoL) of patients has become increasingly important when considering options for individual patient care and in allocating health-care resources between competing treatments. Chronic iron overload is a major complication of potentially lifesaving blood transfusions used in the ongoing treatment of hematological conditions such as the thalassemias, myelodysplastic syndrome, and sickle cell disease. Excess iron is deposited in various tissues of the body, particularly the liver, heart, and endocrine organs [1] . Once the body's storage capacity is exceeded, free iron catalyzes the formation of highly reactive hydroxyl radicals which lead to membrane damage and denaturation of proteins. This process leads to tissue damage and ultimately to significant morbidity and mortality.
The current standard of care for chronic iron overload is the subcutaneous administration of deferoxamine, for 8 to 12 hours per day, 5 to 7 days a week. This treatment regimen in some cases leads not only to poor compliance, and hence a reduction in the extent of effective iron chelation, but also to a reduction in HRQoL.
Deferasirox, a recently developed treatment for transfusional iron overload, is a once-daily oral therapy [2, 3] . Evidence to date indicates that this treatment has equivalent efficacy to subcutaneous deferoxamine [2] ; however, little is known about the comparative HRQoL impacts of these alternative treatments. There has been a dearth of research exploring the HRQoL impacts of iron overload treatments including the route of administration, although a preliminary study using the Sickness Impact Profile indicated that route of administration affected patientperceived HRQoL [4] .
The current study aimed to elicit the strength of community preferences (utility) between the different modes of administration where the current standard treatment, deferoxamine (subcutaneous administration), was compared with the new once-daily oral treatment, deferasirox.
Methods
A community sample of 120 individuals was asked to participate in a time trade-off (TTO) exercise. The participants of the study were registrants of a market research firm and were systematically sampled from four geographic regions across Sydney, Australia. These regions represented a range of sociodemographic characteristics, and a balanced sample across socioeconomic status, age, and sex was recruited. Respondents received a fee of AUS$45 at the end of each interview. Ethics approval for the study was not required as the registrants were not patients, no interventions were involved, and they had previously consented to occasional surveys.
At interview, each participant was presented with standardized background information on iron overload and its treatment, together with short descriptions (vignettes or scenarios) of three health states for patients with thalassemia. These vignettes were designed to be clinically and domestically realistic, and easily understood. Each of the vignettes is presented in Box 1, and can be summarized as follows: 1) an anchor/base state that described a patient who has iron chelation without describing the treatment itself; 2) the anchor state plus iron chelation via a subcutaneous infusion; and 3) the anchor state plus iron chelation via a once-daily oral medication.
An iterative approach was used to develop the vignettes. That is, draft vignettes were shown to hematology clinical specialists and people currently treated for thalassemia to ensure that the descriptions were clinically accurate, reflected the experiences of the target patient population, and accurately represented the necessary dimensions of HRQoL. Consultation on the content of those vignettes continued until consensus was achieved between the researchers, clinicians, and people with thalassemia.
Following standard TTO methodology [5, 6 ], participants were then asked systematically to make a series of hypothetical trade-offs between living in each of these health states for 10 years, or shorter periods in "normal health." At the point of indifference, where the participant was unable to choose between 10 years in the alternative health state and the period of normal health on offer, the participant implicitly assigned equivalent value to the alternatives offered. The "quality" weight then assigned, known as the level of "utility" in economic evaluation, is the ratio of the time in normal health on offer to the time in the alternative health state (10 years).
To avoid ordering bias, respondents were randomized to respond to either health state (2) or (3) immediately after their response to the anchor state. These health states were not labeled in terms of the iron chelator included and differed only in their description of the mode of treatment administration. The range of possible utility values was a maximum of 1 for full health and a minimum of 0 for death.
Five novice interviewers received a training for two full days by an experienced "master" interviewer. This involved theoretical background, up to eight training interviews with administrative staff, observation of at least 16 interviews and accompanying commentary by the trainer. These initial 16 interviews were undertaken with one interviewer observing. During the study, quality control interviewer meetings were held after every 20 to 25 interviews. Given that the TTO exercise can be difficult for some interviewees and limited relevant data were available to assist with sample size estimation, 16 initial interviews were conducted. Investigators and interviewers reviewed each initial case to identify potential difficulties participants were having with understanding the TTO technique, whether interviewers were consistent with their oral presentation of vignettes and how they reached the point of indifference, and that the content of the vignettes was acceptable to participants. No anomalies were revealed, so no changes were made to the vignettes or procedures.
Based on the first 16 interviews, the standard deviation across the three vignettes ranged from 0.29 to 0.35. We then estimated that at least 100 complete interviews would give sufficient power to detect a difference in mean utility scores of 0.1 where alpha = 0.05, power = 80%. A 10% difference in mean utility score was chosen because it was considered that this represented an important difference in QoL [7] . As the primary objective of this study was to compare individual respondents' scores across the two routes of administration, the nonparametric Wilcoxon-signed rank test was used. With TTO, as some respondents may have extreme points of view and/or will not trade, this conservative nonparametric procedure was preferred over the parametric paired t-test equivalent. Differences in utility values between demographic factors were explored with the MannWhitney U-test (two groups) or Kruskal-Wallis test (two or more groups). The possible effects of vignette ordering bias were examined using the Mann-Whitney U-test. All analyses were undertaken using spss version 14 (SPSS Inc., Chicago, IL, USA).
Box 1 Vignettes
Anchor health state Jenny/Jack has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood by having blood transfusions every month. At the end of each month, before the transfusions, Jenny/Jack feels a bit tired but she/he can do all the things that her/his friends can do. Jenny/Jack understands that the transfusions prevent some of the complications of thalassemia but result in too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver damage, diabetes and possibly a shorter life. She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for all of her/his life.
Subcutaneous desferrioxamine
Ann/Andrew has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood by having blood transfusions every month. At the end of each month, before the transfusions, Ann/Andrew feels a bit tired but she/he can do all the things that her/his friends can do. Ann/Andrew understands that the transfusions prevent some of the complications of thalassemia but result in too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver damage, diabetes and possibly a shorter life. She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for all of her/his life. To treat the iron overload, Ann/Andrew has a subcutaneous infusion on about 5 days of the week. She/He is able to prepare the infusion, medicine and needle by herself/himself and has become quite good at inserting it into her/his skin. The medicine is delivered by a small battery powered pump. The infusion takes about 8 to 12 hours and during this time the pump is strapped to her/his arm during the day as she/he moves around or sits next to the bed at night. She/He changes the place on her/his body where she/he inserts the needle on a regular basis, but often her/his skin gets sore around where she/he has had the needle.
Oral Defarasirox
Betty/Bob has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood by having blood transfusions every month. At the end of each month, before the transfusions, Betty/Bob feels a bit tired but she/he can do all the things that her/his friends can do. Betty/Bob understands that the transfusions prevent some of the complications of thalassemia but result in too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver damage, diabetes and possibly a shorter life. She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for all of her/his life. To treat the iron overload, Betty/Bob takes a tablet once a day every day of the week. She/He takes this tablet by dissolving it in a glass of water. The dissolved tablet is tasteless, makes the water cloudy. Betty/Bob has no problem drinking it.
Full Health
Carol/Ken is free from any major illnesses, does not need to take any medications and has full quality of life.
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Results
A total of 110 interviews were undertaken. About half were female, with an approximately even age distribution between 20 years and 60 years, 52% were married or de facto with children, 61% were in fulltime employment, 41% had a university education, and there was an approximately even distribution across income levels (Table 1) . Of those who were employed the most frequent areas of occupation were information technology (15%), followed by accounting/legal (13%), health/science fields (13%), and sales/retail (12%).
As part of an interview quality control process in the current study, each interviewee was observed for evidence that they had misunderstood the TTO process or provided illogical answers. No interviewees exhibited substantial misunderstanding, therefore, all data were included in the analysis.
The TTO exercise revealed a quite different distribution of preferences for the three health states (Fig. 1) and a mean (median) utility of 0.75 (0.80) for the anchor state, 0.61 (0.66) for the subcutaneously infused iron chelator, and 0.85 (0.93) for the oncedaily oral iron chelator (Fig. 2) .
The mean (median) difference of 0.23 (0.27) in the utility value for the two treatments was highly statistically significant (Wilcoxon-signed rank test, P < 0.001). Treatment with the subcutaneously infused agent was associated with a lower mean (median) utility value, being 0.13 (0.14) below that for the anchor state (P < 0.001). In contrast, treatment with a once-daily oral iron chelator had a mean (median) utility value that was 0.10 (0.13) (P < 0.001) higher than the anchor state. These results were consistent across respondent subgroups according to age, sex, employment status, income, and education (Table 1) . No systematic differences in utility scores were observed when the order of vignette presentation was considered. For subcutaneous treatment, the median (interquartile range [IQR] ) utility when the subcutaneous treatment vignette was presented first (median 0.65, IQR 0.50-0.85, n = 51) was similar to that when the oral treatment vignette was presented first (median 0.67, IQR 0.38-0.89, n = 59, Mann-Whitney U = 1418, P = 0.61). For oral treatment, the median (IQR) utility when the subcutaneous treatment vignette was presented first (median 0.95, IQR 0.80-1.00, n = 51) was similar to that when the oral treatment vignette was presented first (median 0.90, IQR 0.80-0.95, n = 59, Mann-Whitney U = 1287, P = 0.19).
Conclusions
The study sought to estimate the strength of preference society places on receiving treatment for iron overload through a subcutaneous versus an oral administration route. People from the general population were selected to obtain a societal perspective rather than a patientspecific perspective. These community-based preferences reflect "utility" values as applied in economic evaluations and are more informative than patientbased preferences when making judgments about the allocation of societal resources within health care [5, 6] .
Although the applicability of community-based preferences to decisions regarding patient treatment at the individual patient level is limited, a recent review highlighted that the mode of administration of iron chelation therapy is perceived by patients with thalassemia as an important determinant of HRQoL [8] . Our results clearly show that community respondents prefer the health state in which patients receive the daily oral treatment compared with that where patients receive subcutaneous treatment. The mean difference was large: 0.23 (median 0.27) units. In QoL research, a change of 10% of a scale is regarded as at least a minimal important difference [7] .
The mean utility value associated with the health state in which the oral treatment (deferasirox) is used was relatively high (mean 0.85), suggesting respondents appear willing to only give up a median of 11 months of life out of 10 years. This implies that most respondents regard having iron overload that is treated by an oral daily treatment as still offering good HRQoL. In contrast, having iron overload that is treated with subcutaneous infusion on about 5 days of the week is regarded as a suboptimal health state; people are willing to give up about 3.5 years of life out of 10 years to live in normal health.
Previous work undertaken to investigate a similar question in the area of intravenous versus oral ganciclovir for maintenance treatment of AIDS-related cytomegalovirus retinitis showed a significant impact of the route of drug administration on the utility value that patients associate with treatment. In this study, utility differences of greater than 0.3 units were reported, slightly larger than what we observed in the present study [9] .
That a preference exists for oral therapy compared with subcutaneous infusion is not surprising. This study provides further confirmation of the strength of that preference. When compared with HRQoL studies in other clinical contexts, the reduction in HRQoL in our study of 0.23 from oral administration to subcutaneous infusion is similar to that reported from normal health to angina and congestive heart failure [10] , less than 4 months post lung transplant [11] , or for an acute depressive episode [12] .
In this study, we aimed to ensure the utilities extracted by the TTO exercise resulted in consistent and reliable data. In previous studies, acceptable reliability data have been reported for the TTO technique where intraclass correlation coefficient estimates ranged from 0.61 to 0.88 [13] [14] [15] . In the present study, the widest range of preference scores was observed for subcutaneous administration (Fig. 1) , but a clear pattern of higher utility was observed for the oral route. As we presented only three TTO exercises to each participant (anchor, intravenous, and oral), we included a randomization procedure for the latter two vignettes with the aim of reducing ordering effects and potential for consequent systematic bias. The clear differentiation between the latter two vignettes implies that this was achieved and the large variation of responses to the subcutaneous infusion presumably reflects wide community preferences for the QoL this administration procedure confers.
A potential weakness of the study is the lack of population-based sampling. The sample did include a substantial number of respondents from higher socioeconomic backgrounds and it is unknown how other population subgroups may have responded to the vignettes. The study could have been improved through the inclusion of cognitive debriefing interviews to ratify respondent's answers and inclusion of formal test-retest studies to assess statistical reliability of the TTO interviews.
Although this study incorporated a purposeful sampling, rather than a more rigorous population-based sampling approach, the consistency of the results across the respondents suggests that they may be generalizable across members of the community. These results indicate that society associates oral administration of an iron chelator with an advancement in the HRQoL of patients who require such treatment.
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